Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Fadraciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Cyc065, 1070790-89-4, Cyc-065, Fadraciclib , cyc065, Yet2xnu791
    Molecular Formula
    C21H31N7O
    Molecular Weight
    397.5  g/mol
    InChI Key
    DLPIYBKBHMZCJI-WBVHZDCISA-N
    FDA UNII
    YET2XNU791
    Fadraciclib is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol
    2.1.2 InChI
    InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1
    2.1.3 InChI Key
    DLPIYBKBHMZCJI-WBVHZDCISA-N
    2.1.4 Canonical SMILES
    CCC(C(C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C
    2.1.5 Isomeric SMILES
    CC[C@@H]([C@@H](C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C
    2.2 Other Identifiers
    2.2.1 UNII
    YET2XNU791
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Cyc065

    2.3.2 Depositor-Supplied Synonyms

    1. Cyc065

    2. 1070790-89-4

    3. Cyc-065

    4. Fadraciclib

    5.  Cyc065

    6. Yet2xnu791

    7. (2r,3s)-3-((6-(((4,6-dimethylpyridin-3-yl)methyl)amino)-9-isopropyl-9h-purin-2-yl)amino)pentan-2-ol

    8. 1070790-89-4 (free Base)

    9. (2r,3s)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol

    10. 2-pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9h-purin-2-yl)amino)-, (2r,3s)-

    11. Cyc065 Free Base

    12. Cyc-065 Free Base

    13. Fadraciclib [inn]

    14. Unii-yet2xnu791

    15. Fadraciclib [who-dd]

    16. Chembl3655762

    17. Schembl13300946

    18. Gtpl10461

    19. Bdbm106950

    20. Bcp19571

    21. Ex-a2830

    22. Nsc806387

    23. Cs-7615

    24. Db15425

    25. Nsc-806387

    26. Ac-31595

    27. Bc175840

    28. Hy-101212

    29. Us8592581, 1

    30. A903453

    2.4 Create Date
    2008-10-27
    3 Chemical and Physical Properties
    Molecular Weight 397.5 g/mol
    Molecular Formula C21H31N7O
    XLogP33.3
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count8
    Exact Mass397.25900864 g/mol
    Monoisotopic Mass397.25900864 g/mol
    Topological Polar Surface Area101 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity507
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1